bpc 157 spinal stenosis Body Protecting Compound 157 (BPC-157

(2004) Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults

Their primary therapeutic actions include stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying to promote satiety, and acting on hypothalamic appetite centers to reduce hunger and caloric intake

Peer review Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work

If you notice persistent or worsening pain, significant swelling, warmth, pus, fever, or a rash, please contact us promptly, as these symptoms may indicate an allergic reaction or infection